---
document_datetime: 2024-12-16 15:05:10
document_pages: 20
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/naglazyme-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: naglazyme-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 12.5548533
conversion_datetime: 2025-12-25 01:11:48.01925
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Naglazyme

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0097              | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product | 12/12/2024                          |                                             | SmPC                             |           |
| IA/0096              | A.7 - Administrative change - Deletion of manufacturing sites                                                                                | 06/09/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0094            | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                            | 11/03/2024   | n/a        |                       |                                                                                                                                                               |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0093            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 08/08/2023   | n/a        |                       |                                                                                                                                                               |
| IB/0091/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other | 06/07/2023   | n/a        |                       |                                                                                                                                                               |
| II/0090            | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/05/2023   | n/a        |                       |                                                                                                                                                               |
| PSUSA/1515/ 202205 | Periodic Safety Update EU Single assessment - galsulfase                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12/01/2023   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                             |
| II/0086            | Update of section 4.1 of the SmPC to remove information on limited safety data in children under 5 years of age, based on the results from the final                                                                                                                                                                                                                                                                                                                                                                        | 27/01/2022   | 01/04/2022 | SmPC, Annex II and PL | The wording of the therapeutic indication in section 4.1 of the SmPC was amended to remove the following statements regarding safety in children aged below 5 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| study report from the VI Clinical Surveillance Specific Obligation Product Information. undertaken to MPS VI, to evaluate data from Naglazyme information on the lactation, growth and Naglazyme treated effects of Naglazyme years of age. Further, updated to remove authorisation under Annex II was updated in In addition, the statement and corresponding black the SmPC and the Package was aligned with the latest 10.2. The revised RMP order to remove gastrointestinal hepatic impairment and list of important potential compression and neutralising potential risks and pregnant missing information. As updates, specific adverse questionnaires for spinal removed in Annex 4 of C.I.11.b - Introduction   | Mucopolysaccharidosis (MPS) Program (CSP) listed as a (SOB 002) in the Annex II of the This observational CSP was characterise the natural progression of the long-term safety and efficacy treatment, to collect effect of Naglazyme treatment on development of infants of mothers, and to evaluate the treatment on children under 5 section 5.1 of the SmPC was reference to marketing exceptional circumstances and years: A key issue is suffering from a children <5 years study. Limited data age (see section The final wording of Naglazyme is therapy in patients 4-sulfatase section 5.1). For more Product   | to treat children aged <5 years severe form of the disease, even though were not included in the pivotal phase 3 are available in patients < 1 year of 5.1) the indication: indicated for long-term enzyme replacement with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine deficiency; Maroteaux-Lamy syndrome) (see information, please refer to the Summary of Characteristics.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                    | authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |                   |                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/1515/ 202105 | Periodic Safety Update EU Single assessment - galsulfase                                                                                                                                              | 13/01/2022 | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                            |
| S/0087             | Annual re-assessment.                                                                                                                                                                                 | 11/11/2021 | n/a        |                   | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Naglazyme should be maintained.                                                                                                           |
| PSUSA/1515/ 202005 | Periodic Safety Update EU Single assessment - galsulfase                                                                                                                                              | 14/01/2021 | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                            |
| S/0083             | Annual re-assessment.                                                                                                                                                                                 | 12/11/2020 | 11/01/2021 | Annex II          | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Naglazyme should be varied, as SOB 003 is considered fulfilled and thus is removed from the list of specific obligations to be completed. |
| IB/0085            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                         | 14/12/2020 | 03/12/2021 | SmPC and Annex II |                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0082            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                         | 27/08/2020 | 11/01/2021 | Annex II          |                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| II/0081            | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   | 14/05/2020   | n/a        |                 |                                                                                                                                                                                                                                                                    |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0078             | Annual re-assessment.                                                                                                                                                                                                                                                                            | 27/02/2020   | 05/05/2020 | SmPC and PL     | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Naglazyme should be maintained. |
| PSUSA/1515/ 201905 | Periodic Safety Update EU Single assessment - galsulfase                                                                                                                                                                                                                                         | 30/01/2020   | 03/04/2020 | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/1515/201905.                                                                                                                          |
| IG/1141            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                           | 12/12/2019   | n/a        |                 |                                                                                                                                                                                                                                                                    |
| IA/0077            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                    | 10/05/2019   | 03/04/2020 | Annex II and PL |                                                                                                                                                                                                                                                                    |
| IG/1083            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                           | 08/04/2019   | n/a        |                 |                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| IA/0075/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of                                   | 11/03/2019   | n/a        |                        |                                                                                                                                                                                                                                                                    |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0073             | 11th annual re-assessment                                                                                                                                                                                                                                  | 28/02/2019   | n/a        |                        | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Naglazyme should be maintained. |
| PSUSA/1515/ 201805 | Periodic Safety Update EU Single assessment - galsulfase                                                                                                                                                                                                   | 17/01/2019   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |
| II/0070            | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol | 26/07/2018   | n/a        |                        |                                                                                                                                                                                                                                                                    |
| T/0072             | Transfer of Marketing Authorisation                                                                                                                                                                                                                        | 02/07/2018   | 13/07/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                    |
| N/0071             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                           | 10/04/2018   | 13/07/2018 | Labelling              |                                                                                                                                                                                                                                                                    |
| PSUSA/1515/ 201705 | Periodic Safety Update EU Single assessment - galsulfase                                                                                                                                                                                                   | 11/01/2018   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| S/0067             | Annual re-assessment.                                                                                                                                                                            | 09/11/2017   | n/a        |                        |                                   |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IB/0069            | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                 | 24/10/2017   | n/a        |                        |                                   |
| PSUSA/1515/ 201605 | Periodic Safety Update EU Single assessment - galsulfase                                                                                                                                         | 12/01/2017   | n/a        |                        | PRAC Recommendation - maintenance |
| S/0065             | Annual re-assessment.                                                                                                                                                                            | 15/12/2016   | n/a        |                        |                                   |
| IG/0658            | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                       | 02/02/2016   | 09/01/2017 | SmPC, Labelling and PL |                                   |
| PSUSA/1515/ 201505 | Periodic Safety Update EU Single assessment - galsulfase                                                                                                                                         | 14/01/2016   | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0063            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 10/12/2015   | n/a        |                        |                                   |
| S/0060             | Annual re-assessment.                                                                                                                                                                            | 19/11/2015   | n/a        |                        |                                   |
| IG/0629            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                               | 05/11/2015   | n/a        |                        |                                   |
| II/0059            | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                              | 17/09/2015   | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                |            |     |                                   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0058   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                       | 28/05/2015 | n/a |                                   |
| IB/0057/G | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.d.1.b.3 - Stability of AS - Change in the storage conditions - Change in storage conditions of the AS B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other | 14/04/2015 | n/a |                                   |
| IB/0055   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                  | 26/01/2015 | n/a |                                   |
| PSUV/0054 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 09/01/2015 | n/a | PRAC Recommendation - maintenance |
| IB/0056   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                  | 12/12/2014 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| S/0053    | 7thAnnual Re-assessment.                                                                                                                                                                                                                                                                                                         | 20/11/2014   | n/a        |                 | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of Naglazyme should be maintained.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0471   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                  | 04/08/2014   | n/a        |                 |                                                                                                                                                                                                                                                                      |
| IG/0458   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                       | 09/07/2014   | 15/12/2014 | Annex II and PL |                                                                                                                                                                                                                                                                      |
| PSUV/0046 | Periodic Safety Update                                                                                                                                                                                                                                                                                                           | 09/01/2014   | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                    |
| IAIN/0049 | C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring                                                                                                                                                     | 08/01/2014   | 15/12/2014 | SmPC and PL     |                                                                                                                                                                                                                                                                      |
| IB/0047/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 19/12/2013   | 15/12/2014 | Annex II and PL |                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|         | for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |     | manufacturing site   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------|
| IB/0048 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                          | 05/12/2013 | n/a |                      |
| S/0043  | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                     | 21/11/2013 | n/a |                      |
| IB/0044 | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                              | 09/09/2013 | n/a |                      |
|         | This was an application for a group of variations. B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier A.7 - Administrative change - Deletion of manufacturing sites                           | 11/06/2013 | n/a | IA/0042/G            |

<div style=\"page-break-after: always\"></div>

| IB/0041   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                            | 26/04/2013   | n/a        |             |                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------|
| IA/0040/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding batch release) | 26/04/2013   | n/a        |             | manufacturer for |
| IAIN/0039 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                  | 26/02/2013   | n/a        |             |                  |
| S/0034    | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                           | 20/09/2012   | 15/11/2012 | SmPC and PL |                  |
| IG/0207   | C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV                                                                                                                                                                                                                                                                                                         | 03/08/2012   | n/a        |             |                  |
| IG/0177   | C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV                                                                                                                                                                                                                                                                                | 25/05/2012   | n/a        |             |                  |
| II/0033/G | This was an application for a group of variations. Changes to the manufacture of the active substance                                                                                                                                                                                                                                                                                                           | 15/12/2011   | 15/12/2011 |             |                  |

<div style=\"page-break-after: always\"></div>

|         | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                                                                                                                                               |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0030 | Update of sections 4.3, 4.4 and 4.8 of the SmPC to reflect the conclusions of a cumulative review of all post-marketing adverse events. This review was requested by the CHMP, following review of PSUR-7. The MAH also took this opportunity to update the MedDRA terms used to describe adverse events collected during clinical studies involving Naglazyme. The Package Leaflet has been updated accordingly and Annex II has been updated with a minor linguistic correction. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 22/09/2011 | 20/10/2011 | SmPC and PL | The MAH has conducted two through reviews; one using clinical trial data from 5 studies and the second using post- marketing spontaneous data. Following these reviews a number of updates have been proposed to the Naglazyme product information. The re-analysis of the 5 clinical trials (ASB-00-001, ASB- 04-01, ASB-03-05, ASB-03-06 and ASB-008) identified a total 59 patients who had received at least one dose of Naglazyme. No treatment related deaths were identified from these clinical studies. Following the re-analysis of data set from study ASB-03-05, the MAH has proposed the deletion of face oedema and the addition of arthralgia, rash, and hearing impaired to Table 1 in section 4.8 of the SmPC. The MAH proposal to remove Apnoea from Table 1 to the post-marketing section was not endorsed as this ADR was only identified in a clinical study setting. |

<div style=\"page-break-after: always\"></div>

|           |                                                    |            |     | The cumulative review of post-marketing spontaneous reports revealed a number of ADRs that were reported more frequently in Naglazyme-treated subjects. Most of these were hypersensitivity type reactions that occurred during Naglazyme infusion. The MAH proposed to strengthen the wording relating to hypersensitivity reactions and management in section 4.4. of the Naglazyme SmPC. Five cases of CCF were identified however, 3 patients had worsening of pre-existing CCF, and it is not known whether such patients were included in clinical trials. The MAH will continue to monitor cases of CCF as part of routine Pharmacovigilance, and will update the Risk Management Plan should this term become a more clearly identified risk. According to the data presented, the hypersensitivity reactions in association with Naglazyme therapy were of different degrees of severity ranging from very severe, life- threatening to mild symptoms. Whilst the CHMP acknowledge that other treatment options for MPS VI patients are limited, rechallenge in patients who have experienced a severe or life-threatening hypersensitivity to Naglazyme is not considered to be acceptable. Therefore, the CHMP was of the view that Naglazyme should be contraindicated in cases of severe or life-threatening hypersensitivity, if hypersensitivity is not controllable. This variation does not change the benefit/risk balance for   |
|-----------|----------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0032/G | This was an application for a group of variations. | 13/10/2011 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | system as described in the DDPS - Other variation C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD                                                   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0028  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18/11/2010 | 26/01/2011 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0031 | Update of Summary of Product Characteristics and Package Leaflet to reflect the results of study ASB- 008 (infant study), as requested by the CHMP following evaluation of this study report as part of the latest Annual Reassessment. Additionally the MAH took the opportunity to update Annex II to reflect the completion of a commitment as per the 4th Annual Reassessment. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 18/11/2010 | 20/10/2010 | SmPC, Annex II and PL | The infant study (ASB-008) is a Phase IV, multi-center, multi-national, open-label, randomized, two-dose level study designed to evaluate the safety and efficacy of two dose levels (1 mg/kg/week and 2 mg/kg/week) of Naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one who have MPS VI. The study started in May 2006 and was completed in April 2009. Four patients completed the study. Although limited by the very small number of patients that could be enrolled and their short follow-up, the conclusions that can be drawn from this study are the following: \" Treatment with Naglazyme did not prevent the progression of skeletal dysplasia and development of hernias in infants less than 2 years of age and, as expected, did not prevent the progression of corneal |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                           |            |            |                   | clouding. \" However, it prevented development or worsening of facial dysmorphism and improved hearing loss to some extent. \" High urinary GAG levels decreased by more than 70%, as was observed with older patients. \" Growth remained essentially normal over this limited follow-up period. \" Some level of improvement in hearing was observed in all subjects. \" The dose of 2 mg/kg/week was not more effective than the current recommended dose of 1 mg/kg/week. Of note, the randomisation allocated the higher dose to the oldest children (aged > 1 year). The overall safety profile of the higher dose of 2 mg/kg/week did not seem different in a clinically meaningful manner from that of the 1 mg/kg/week dose. They were consistent with the safety profile of Naglazyme in previous clinical trials involving older children. No new safety signal emerged in this small group of infants.   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0027 | Change in the manufacture of the drug substance B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs | 23/09/2010 | 29/09/2010 |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| S/0026  | Annual re-assessment.                                                                                                                                                                                     | 20/05/2010 | 06/08/2010 | SmPC and Annex II | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concludes that, overall, the benefit/risk balance for                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                      |            |            |          | the product remains unchanged.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0025 | Additional sites for the manufacture of the drug product and for the control of the drug substance and drug product. Change(s) to the manufacturing process for the finished product | 24/09/2009 | 05/10/2009 |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| S/0021  | Annual Reassessment                                                                                                                                                                  | 23/04/2009 | 01/07/2009 | Annex II | \"The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the product remains favourable. The CHMP agreed that the Marketing Authorisation for Naglazyme should remain under exceptional circumstances and agreed on a revised list of Specific Obligations. The following Specific Obligation has been fulfilled with the annual re-assessment: SOB-4: \"All clinical trial patients are currently receiving the product manufactured by the commercial process. GAG and antibody samples continue to be collected at protocol- specified intervals. A change in nature or frequency of the adverse events and serious adverse events that are collected in an ongoing fashion within these studies will be evaluated to investigate a potential relationship between an observed change in safety parameters and the transition to commercial material and reported in the annual CSP reports and PSURs as appropriate. |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                              |            |            |                        | The MAH commits to analysing the data from patients who have received clinical and then commercial process product to determine if there was any change to safety (antibody formation) or efficacy parameters stemming from the transition to commercial material and will provide this analysis in the clinical study reports for each of these studies when complete. The Clinical Study Reports for all studies are targeted for submission no later than January 2007\".   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0023 | IB_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening IB_37_a_Change in the specification of the finished product - tightening of specification limits | 23/06/2009 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IB/0024 | IB_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening IB_37_a_Change in the specification of the finished product - tightening of specification limits | 18/05/2009 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0020 | IA_01_Change in the name and/or address of the marketing authorisation holder                                                                                                                | 13/02/2009 | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IA/0019 | IA_31_a_Change to in-process tests/limits during manufacture - tightening of in-process limits                                                                                               | 11/08/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| S/0015  | Annual re-assessment.                                                                                                                                                                        | 24/04/2008 | 30/07/2008 | Annex II               | The CHMP, having reviewed the evidence of compliance with the Specific Obligations submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile for Naglazyme, concluded that the benefit/risk ratio for the product remains favourable in the approved indication.                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         |                                                                                          |            |            |                            | The CHMP agreed that the Marketing Authorisation should be kept under exceptional circumstances and agreed on a revised list of Specific Obligations, which can be found in Annex II.C of the product information.                                                                                                                                                                                                     |
|---------|------------------------------------------------------------------------------------------|------------|------------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0018 | Change(s) to the test method(s) and/or specifications for the active substance           | 26/06/2008 | 16/07/2008 |                            |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0017 | Change(s) to the manufacturing process for the active substance                          | 30/05/2008 | 11/06/2008 |                            |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0016 | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size | 23/04/2008 | 23/04/2008 | SmPC, Labelling and PL     |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0014 | IA_05_Change in the name and/or address of a manufacturer of the finished product        | 04/10/2007 | n/a        | Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0013 | Change(s) to the manufacturing process for the active substance                          | 20/09/2007 | 01/10/2007 |                            |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0012 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale               | 05/07/2007 | n/a        | SmPC                       |                                                                                                                                                                                                                                                                                                                                                                                                                        |
| S/0011  | Annual re-assessment.                                                                    | 26/04/2007 | 02/07/2007 | SmPC and PL                | The CHMP, having reviewed the evidence of compliance with the Specific Obligations submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile for Naglazyme, concluded that the benefit/risk ratio for the product remains favourable in the approved indication. The CHMP agreed that the Marketing Authorisation should be kept under exceptional circumstances and agreed on a |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                  | revised list of Specific Obligations, which can be found in Annex II.C of the product information.   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|------------------------------------------------------------------------------------------------------|
| II/0010 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                | 22/02/2007 | 26/02/2007 |                  |                                                                                                      |
| II/0009 | Change(s) to the manufacturing process for the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                                | 24/01/2007 | 29/01/2007 |                  |                                                                                                      |
| II/0007 | Change(s) to the test method(s) and/or specifications for the finished product                                                                                                                                                                                                                                                                                                                                                                                                                                 | 18/10/2006 | 23/10/2006 |                  |                                                                                                      |
| IB/0006 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                     | 18/09/2006 | n/a        | SmPC             |                                                                                                      |
| N/0004  | The Marketing Authorisation Holder (MAH) applied for the addition of the term \"5 mg/5 ml\" in section 4 \"Pharmaceutical form and contents\" of the outer packaging. The MAH also applied for the update of the local representative list of the Package Leaflet to include contact details for all Member States. Additionally corrections were made in section 6 of to the German and French package leaflets. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 07/07/2006 | n/a        | Labelling and PL |                                                                                                      |
| II/0001 | Change(s) to the manufacturing process for the active substance                                                                                                                                                                                                                                                                                                                                                                                                                                                | 27/04/2006 | 04/05/2006 |                  |                                                                                                      |
| IB/0003 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/04/2006 | n/a        | SmPC             |                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IA/0002   | IA_01_Change in the name and/or address of the marketing authorisation holder   | 31/03/2006   | n/a   | SmPC, Labelling and PL   |
|-----------|---------------------------------------------------------------------------------|--------------|-------|--------------------------|